entity

DAPAGLIFLOZIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DAPAGLIFLOZIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

18Connections
0Hypotheses
0Analyses
11Outgoing
5Incoming

Wiki Pages (15)

Knowledge base pages for this entity

Insulin Signaling in Parkinson's Disease

mechanism · 4072 words

NIH Drug Repurposing Program for Neurodegenerative Diseases

institution · 3160 words

Taisho Pharmaceutical

company · 2715 words

Pyroptosis

mechanism · 2592 words

sglt2-inhibitors-neurodegeneration

therapeutic · 2458 words

Outgoing (13)

TargetRelationTypeStr
PARKINSON'S DISEASEprotects_againstdisease0.65
OXIDATIVE STRESSinteracts_withphenotype0.65
OXIDATIVE STRESStargetsphenotype0.65
SEMAGLUTIDEassociated_withdrug0.45
SUPEROXIDEassociated_withphenotype0.45

Incoming (5)

SourceRelationTypeStr
EMPAGLIFLOZINassociated_withdrug0.45
PARKINSON'S DISEASEassociated_withdisease0.45
OXIDATIVE STRESSassociated_withphenotype0.45
TAU PHOSPHORYLATIONassociated_withphenotype0.45
NEUROINFLAMMATIONassociated_withphenotype0.45

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found